TSHR; | |
ACHE; | |
TDP1; EBP; PKM; NOS1; HSD17B1; NOS2; HSD17B10; NOX4; HPGD; ALOX15; ALDH1A1; USP2; TNKS; TNKS2; | |
CFTR; | |
KCNH2; | |
GSK3B; SYK; MAPK1; FLT3; CDK6; CSNK2A1; | |
AR; | |
ESR1; ESR2; | |
KDM4E; | |
MAOA; PTGS2; XDH; | |
HIF1A; TP53; NFKB1; | |
ABCB1; ABCG2; ABCC1; | |
NPC1; MAPT; EBPL; THPO; SIGMAR1; TTR; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | EBP | 3-beta-hydroxysteroid-delta(8),delta(7)-isomerase | Q15125 | CHEMBL4931 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Enzyme_unclassified | NOS1 | Nitric-oxide synthase, brain | P29475 | CHEMBL3568 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | NOS2 | Nitric oxide synthase, inducible | P35228 | CHEMBL4481 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Potassium channels | KCNH2 | HERG | Q12809 | CHEMBL240 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | EBPL | Emopamil-binding protein-like | Q9BY08 | CHEMBL2311238 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | SIGMAR1 | Sigma opioid receptor | Q99720 | CHEMBL287 |
Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.245E-13 | 5.431E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2D6, CYP3A4, NOX4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.517E-13 | 5.481E-10 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2D6, CYP3A4, NOS1, NOS2, XDH |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.153E-11 | 2.131E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.935E-10 | 3.231E-07 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 8.246E-09 | 3.325E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.936E-08 | 6.692E-06 | CYP1A2, CYP2C19, CYP3A4, NOS1 |
BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 3.936E-08 | 1.174E-05 | CDK6, CFTR, CYP1B1, KCNH2, MAPK1, NFKB1, NOS2, PTGS2, TP53 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 8.864E-08 | 2.413E-05 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1 |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.091E-07 | 2.863E-05 | CFTR, HIF1A, MAPK1, NPC1, PTGS2, SYK, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.301E-07 | 5.827E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 3.095E-07 | 7.490E-05 | CYP1A1, HIF1A, NOS1, NOS2, NOX4, PKM, PTGS2, TP53 |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 3.130E-07 | 7.490E-05 | CDK6, CFTR, HIF1A, MAPK1, NOS1, NPC1, PTGS2, SYK, TNKS, TNKS2 |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 4.153E-07 | 9.322E-05 | CFTR, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2D6, CYP3A4, EBP, EBPL, NOX4, PTGS2, SIGMAR1 |
MF | GO:0005215; transporter activity | GO:0008559; xenobiotic transmembrane transporting ATPase activity | 5.670E-07 | 1.187E-04 | ABCB1, ABCC1, ABCG2 |
BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 6.221E-07 | 1.278E-04 | AR, CFTR, ESR1, HIF1A, TNKS, TNKS2, TP53, USP2 |
BP | GO:0008152; metabolic process | GO:0016125; sterol metabolic process | 9.419E-07 | 1.768E-04 | CFTR, CYP19A1, CYP1B1, EBP, EBPL, NPC1 |
BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 1.934E-06 | 3.289E-04 | ABCB1, ABCC1, ABCG2 |
BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 1.973E-06 | 3.330E-04 | AR, CDK6, CSNK2A1, ESR1, FLT3, HIF1A, HPGD, MAPK1, PTGS2, SYK, THPO, TSHR |
BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 2.654E-06 | 4.280E-04 | AR, CYP19A1, ESR1 |
BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 3.525E-06 | 5.454E-04 | MAPT, NOX4, PTGS2, TP53, XDH |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 3.532E-06 | 5.454E-04 | CYP1A2, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006809; nitric oxide biosynthetic process | 4.583E-06 | 6.835E-04 | CYP1B1, NOS1, NOS2 |
CC | GO:0016020; membrane | GO:0098590; plasma membrane region | 5.576E-06 | 8.149E-04 | ABCB1, ABCC1, ABCG2, CFTR, HPGD, MAPK1, MAPT, NOS1, NOX4, PTGS2, SIGMAR1, TSHR |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 6.567E-06 | 9.108E-04 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0047750; cholestenol delta-isomerase activity | 6.567E-06 | 9.108E-04 | EBP, EBPL |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 8.925E-06 | 1.200E-03 | ALOX15, HPGD, PTGS2 |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 1.082E-05 | 1.402E-03 | MAPK1, TNKS, TNKS2 |
CC | GO:0044464; cell part | GO:0005739; mitochondrion | 1.741E-05 | 2.217E-03 | CYP1A1, CYP1B1, CYP2D6, ESR2, GSK3B, HSD17B10, MAOA, MAPK1, NFKB1, NOS1, NOX4, PKM, TP53 |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.967E-05 | 2.406E-03 | CYP2D6, CYP3A4 |
BP | GO:0051179; localization | GO:0099039; sphingolipid translocation | 1.967E-05 | 2.406E-03 | ABCB1, ABCC1 |
MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 1.967E-05 | 2.406E-03 | ALOX15, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.967E-05 | 2.406E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004517; nitric-oxide synthase activity | 1.967E-05 | 2.406E-03 | NOS1, NOS2 |
BP | GO:0051179; localization | GO:0006855; drug transmembrane transport | 2.251E-05 | 2.708E-03 | ABCB1, ABCC1, ABCG2, EBP |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.787E-05 | 3.228E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0051179; localization | GO:0051222; positive regulation of protein transport | 2.988E-05 | 3.424E-03 | ACHE, CFTR, GSK3B, HIF1A, MAPK1, PTGS2, SYK, TP53 |
MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 3.034E-05 | 3.453E-03 | ABCG2, ACHE, FLT3, HPGD, KCNH2, MAPT, NFKB1, NOS2, PTGS2, XDH |
BP | GO:0009987; cellular process | GO:0071345; cellular response to cytokine stimulus | 3.379E-05 | 3.774E-03 | ALOX15, FLT3, GSK3B, HIF1A, MAPK1, NFKB1, NOS2 |
BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 3.815E-05 | 4.091E-03 | CDK6, GSK3B, HIF1A, MAPK1, MAPT, PTGS2, SYK, TP53, XDH |
BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 3.927E-05 | 4.091E-03 | TNKS, TNKS2 |
BP | GO:0051179; localization | GO:1901529; positive regulation of anion channel activity | 3.927E-05 | 4.091E-03 | ABCB1, CFTR |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.927E-05 | 4.091E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 3.927E-05 | 4.091E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.927E-05 | 4.091E-03 | CYP1A2, CYP3A4 |
MF | GO:0005488; binding | GO:0005497; androgen binding | 3.927E-05 | 4.091E-03 | ALDH1A1, AR |
MF | GO:0005488; binding | GO:0050660; flavin adenine dinucleotide binding | 3.999E-05 | 4.127E-03 | NOS1, NOS2, NOX4, XDH |
BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 4.069E-05 | 4.160E-03 | CYP19A1, CYP1A2, CYP3A4 |
BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 4.569E-05 | 4.541E-03 | CYP1B1, HIF1A, PTGS2 |
BP | GO:0009987; cellular process | GO:0043410; positive regulation of MAPK cascade | 4.588E-05 | 4.541E-03 | ALOX15, AR, FLT3, MAPK1, NOX4, SYK, THPO, XDH |
BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 4.920E-05 | 4.762E-03 | CSNK2A1, GSK3B, MAPK1, TNKS |
BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 5.108E-05 | 4.878E-03 | CYP19A1, CYP3A4, ESR1 |
BP | GO:0065007; biological regulation | GO:0051090; regulation of DNA binding transcription factor activity | 5.932E-05 | 5.616E-03 | AR, CYP1B1, ESR1, ESR2, MAPK1, NFKB1, SYK |
MF | GO:0005488; binding | GO:0008013; beta-catenin binding | 5.988E-05 | 5.644E-03 | AR, CSNK2A1, ESR1, GSK3B |
BP | GO:0008152; metabolic process | GO:1901617; organic hydroxy compound biosynthetic process | 6.093E-05 | 5.711E-03 | ALOX15, CFTR, CYP19A1, CYP3A4, EBP |
BP | GO:0008152; metabolic process | GO:0042572; retinol metabolic process | 6.307E-05 | 5.844E-03 | ALDH1A1, CYP1B1, TTR |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 6.534E-05 | 6.003E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 6.970E-05 | 6.324E-03 | ABCC1, ALOX15, SYK |
BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 7.709E-05 | 6.880E-03 | CYP1A1, CYP1A2, HPGD, NFKB1, NOS2, PTGS2 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 7.678E-05 | 6.880E-03 | CSNK2A1, HIF1A, MAPT |
BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 9.229E-05 | 8.038E-03 | MAPK1, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 9.785E-05 | 8.323E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 9.785E-05 | 8.323E-03 | ALOX15, HPGD |
BP | GO:0008152; metabolic process | GO:0046456; icosanoid biosynthetic process | 1.192E-04 | 9.905E-03 | ALOX15, PTGS2, SYK |
MF | GO:0005488; binding | GO:0020037; heme binding | 2.096E-14 | 9.130E-11 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2D6, CYP3A4, NOS1, NOS2, NOX4, PTGS2 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 4.294E-08 | 2.212E-06 | AR; GSK3B; CDK6; NOS2; FLT3; MAPK1; PTGS2; HIF1A; TP53; NFKB1 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.832E-08 | 2.212E-06 | NOS2; MAOA; ALOX15; PTGS2; CYP2C19; CYP3A4; CYP19A1; HSD17B10; EBP; PKM; HSD17B1; CYP1A2; ALDH1A1; CYP1A1; NOS1; XDH |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 6.564E-09 | 1.070E-06 | HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.548E-07 | 5.046E-06 | HSD17B1; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 5.427E-08 | 2.212E-06 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.504E-07 | 9.518E-06 | CYP2D6; MAOA; ALOX15; MAPK1; CYP2C19; PTGS2 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 6.725E-07 | 1.291E-05 | ABCC1; CDK6; ABCB1; CYP1B1; MAPK1; PTGS2; TP53; NFKB1 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 6.834E-07 | 1.291E-05 | PKM; FLT3; MAPK1; TP53; HIF1A |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 9.808E-07 | 1.428E-05 | GSK3B; MAPK1; ESR1; NFKB1; ESR2 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 7.923E-07 | 1.291E-05 | MAOA; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 2.818E-06 | 3.212E-05 | GSK3B; AR; MAPK1; TP53; NFKB1 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.051E-06 | 1.428E-05 | CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 2.378E-06 | 2.982E-05 | CDK6; NOS2; PTGS2; TP53; NFKB1 |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.176E-05 | 1.065E-04 | CDK6; PKM; SYK; MAPK1; TP53; NFKB1 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 7.838E-07 | 1.291E-05 | CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.125E-05 | 1.065E-04 | GSK3B; MAPK1; TP53; ESR1; HIF1A |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 2.956E-06 | 3.212E-05 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 2.238E-05 | 1.737E-04 | GSK3B; CDK6; CSNK2A1; TP53; NFKB1 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.222E-05 | 1.737E-04 | CDK6; MAPK1; TP53; NFKB1 |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 3.313E-05 | 2.160E-04 | GSK3B; SYK; MAPK1; NFKB1 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.091E-05 | 1.737E-04 | CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 4.358E-06 | 4.440E-05 | ABCC1; ABCB1; CFTR; ABCG2 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 3.313E-05 | 2.160E-04 | CDK6; MAPK1; TP53; NFKB1 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 6.150E-05 | 3.713E-04 | GSK3B; MAPK1; MAPT; NOS1; HSD17B10 |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 3.313E-05 | 2.160E-04 | NOS2; MAPK1; PTGS2; NFKB1 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.968E-05 | 2.160E-04 | ABCB1; CYP3A4; CFTR; ABCG2 |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.985E-04 | 1.044E-03 | GSK3B; CDK6; SYK; MAPK1; TP53; NFKB1 |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.465E-04 | 7.960E-04 | GSK3B; SYK; CSNK2A1; TP53; NFKB1 |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.274E-04 | 7.158E-04 | NOS2; MAPK1; HIF1A; NFKB1 |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 8.566E-05 | 4.987E-04 | SYK; CSNK2A1; PTGS2; NFKB1 |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 2.293E-04 | 1.133E-03 | GSK3B; MAPK1; TP53; NFKB1 |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.293E-04 | 1.133E-03 | ABCC1; MAPK1; TP53; NFKB1 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 3.396E-04 | 1.538E-03 | GSK3B; MAPK1; TP53; NFKB1 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 4.835E-04 | 1.993E-03 | CDK6; MAPK1; TP53; NFKB1 |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.015E-03 | 3.677E-03 | SYK; NOS2; MAPK1; NFKB1 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.647E-03 | 5.370E-03 | MAPK1; TP53; HIF1A; ESR1 |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.058E-03 | 3.749E-03 | HPGD; FLT3; TP53; NFKB1 |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.532E-03 | 5.095E-03 | MAPK1; CFTR; NFKB1; TSHR |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 3.712E-04 | 1.635E-03 | CDK6; MAPK1; TP53 |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 2.981E-04 | 1.388E-03 | GSK3B; MAPK1; TP53 |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 3.912E-04 | 1.678E-03 | FLT3; MAPK1; NFKB1 |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 5.758E-04 | 2.235E-03 | CDK6; MAPK1; TP53 |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 7.455E-04 | 2.826E-03 | CDK6; MAPK1; TP53 |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 5.012E-04 | 1.993E-03 | GSK3B; MAPK1; TP53 |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.948E-03 | 6.226E-03 | MAPK1; ESR1; ESR2 |
hsa00330 | Arginine and proline metabolism_Homo sapiens_hsa00330 | 2.653E-04 | 1.272E-03 | NOS2; MAOA; NOS1 |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 3.753E-03 | 1.055E-02 | MAPK1; MAPT; TP53; NFKB1 |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 2.629E-03 | 7.792E-03 | MAPK1; PTGS2; NFKB1 |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 2.242E-03 | 6.895E-03 | NOS2; MAPK1; NFKB1 |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 2.242E-03 | 6.895E-03 | GSK3B; MAPK1; NFKB1 |
hsa05133 | Pertussis_Homo sapiens_hsa05133 | 8.746E-04 | 3.240E-03 | NOS2; MAPK1; NFKB1 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 5.012E-04 | 1.993E-03 | ALOX15; CYP2C19; PTGS2 |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 3.207E-03 | 9.333E-03 | NOS2; MAPK1; NFKB1 |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 5.174E-03 | 1.383E-02 | MAPK1; TP53; NFKB1 |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.300E-03 | 4.416E-03 | NOS2; MAPK1; NFKB1 |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 4.392E-03 | 1.213E-02 | SYK; MAPK1; NFKB1 |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 3.687E-03 | 1.054E-02 | GSK3B; CDK6; TP53 |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 5.382E-03 | 1.415E-02 | GSK3B; CSNK2A1; TP53 |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 9.550E-03 | 2.224E-02 | GSK3B; MAPK1; NFKB1 |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.110E-02 | 2.445E-02 | CSNK2A1; TP53; NFKB1 |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 1.142E-02 | 2.472E-02 | GSK3B; MAPK1; NFKB1 |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 2.665E-02 | 4.722E-02 | GSK3B; TP53; NFKB1 |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 2.643E-02 | 4.722E-02 | MAPK1; NFKB1 |
hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 2.595E-02 | 4.722E-02 | GSK3B; MAPK1 |
hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 2.268E-02 | 4.400E-02 | SYK; MAPK1 |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 2.313E-02 | 4.436E-02 | TP53; NFKB1 |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 2.002E-02 | 3.979E-02 | GSK3B; MAPK1 |
hsa04713 | Circadian entrainment_Homo sapiens_hsa04713 | 2.359E-02 | 4.471E-02 | MAPK1; NOS1 |
hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 2.595E-02 | 4.722E-02 | NOS2; NFKB1 |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 2.643E-02 | 4.722E-02 | MAPK1; HIF1A |
hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 2.045E-02 | 4.016E-02 | THPO; FLT3 |
hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 2.643E-02 | 4.722E-02 | MAPK1; PTGS2 |
hsa04146 | Peroxisome_Homo sapiens_hsa04146 | 1.832E-02 | 3.687E-02 | NOS2; XDH |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 1.256E-02 | 2.625E-02 | SYK; MAPK1 |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 8.655E-03 | 2.075E-02 | PTGS2; TSHR |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.475E-02 | 3.006E-02 | CSNK2A1; MAPK1 |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 9.884E-03 | 2.238E-02 | MAPK1; HIF1A |
hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 9.884E-03 | 2.238E-02 | MAPK1; NOS1 |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 1.020E-02 | 2.278E-02 | MAPK1; PTGS2 |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.187E-02 | 2.512E-02 | MAPK1; HIF1A |
hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 1.292E-02 | 2.665E-02 | CDK6; TP53 |
hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 8.955E-03 | 2.116E-02 | MAPK1; NFKB1 |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.152E-02 | 2.472E-02 | MAPK1; NFKB1 |
hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 8.359E-03 | 2.034E-02 | GSK3B; TP53 |
hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 7.223E-03 | 1.784E-02 | NOS1; TP53 |
hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 6.420E-03 | 1.635E-02 | PKM; MAPK1 |
hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 6.683E-03 | 1.676E-02 | MAOA; NFKB1 |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 4.720E-03 | 1.282E-02 | MAPK1; TP53 |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 5.910E-03 | 1.529E-02 | CYP3A4; XDH |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 2.382E-03 | 7.190E-03 | MAPK1; TP53 |
hsa00220 | Arginine biosynthesis_Homo sapiens_hsa00220 | 1.131E-03 | 3.922E-03 | NOS2; NOS1 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 6.096E-05 | 3.713E-04 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
G00-G99: Diseases of the nervous system G00-G99 | Headache | G43-G44, R51 | NOS1 |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
C00-D49: Neoplasms | Cancer | C00-C96 | ABCB1; AR; GSK3B; HIF1A; SYK; TP53; MAPK1; FLT3; FLT3; NFKB1; ACHE; ESR1; ESR1; PTGS2; CSNK2A1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1; ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | SYK; EBP; PTGS2; PTGS2; PTGS2; PTGS2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; PTGS2 |
C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ESR1 |
A00-B99: Certain infectious and parasitic diseases | Septic shock | A41.9 | NOS2 |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; PTGS2; PTGS2; PTGS2 |
NA: NA | Male hypogonadism | NA | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | NOS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
NA: NA | Upper abdominal bloating | NA | ACHE |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; ACHE; ACHE; ACHE; MAOA; PTGS2; MAPT |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | SYK |
C00-D49: Neoplasms | AML | NA | FLT3 |
NA: NA | Menopausal disorder | NA | ESR1 |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | TTR |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ESR1 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3 |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; CYP3A4; MAOA |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; NOS2 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
C00-D49: Neoplasms | CLL | NA | FLT3 |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
NA: NA | GIST | NA | FLT3 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; PTGS2; ABCC1; ABCC1 |
NA: NA | Gonorrheal vaginitis | NA | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2 |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | SYK; NOS2; PTGS2 |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | ABCB1; PTGS2 |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
NA: NA | Joint and muscular pain | NA | PTGS2 |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS2; PTGS2 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | GSK3B |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | NOS2 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; ACHE; ESR1; NOS2; PTGS2; PTGS2; PTGS2; PTGS2; PKM |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; MAOA |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic kidney disease | E11.22 | NOS2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; TP53 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | SYK |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3 |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
C00-D49: Neoplasms | Ovarian cancer | C56 | ABCB1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; PTGS2; ABCC1 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | SYK; SYK; NOS2; PTGS2 |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2 |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Endotoxic shock | R57.8 | NOS2 |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; PTGS2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
C00-D49: Neoplasms | Solid tumours | C00-D48 | ABCB1; HIF1A; SYK; TP53; MAPK1; FLT3; PKM |
A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
NA: NA | Postmenopausal disorder | NA | ESR1 |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2 |
C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; ESR1; ESR1 |
C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |